| N (Node) | ycN1 |
| Date of diagnosis | 2022/11/15 |
| Height, cm | |
| Concomitant Diseases | No |
| Lab Tests | CBC: 30-Apr-2024: RBC: 4.1*1012/L; HGB: 138 g/L; PLT: 125*109/L; WBC: 13.21*109/L; NEU: 69%; LYM: 24%; MON: 7%; ESR 8 mm/hour. Biochemistry: 26-Apr-2024: Total protein: 62 g/L; Direct bilirubin: 14.7 μmol/L; Creatinine: 79.7 μmol/L; Urea: 6 mmol/L |
| Treatment of Concomitant Diseases | No |
| M (Metastasis) | ycM1 |
| Drinking History | Non-drinker |
| Biomarkers | 15-Nov-2022: ER negative; PR negative; HER2 negative; Ki-67 70% |
| Race | Caucasian |
| Stage of disease | IV |
| Treatment | Chemotherapy: 10 courses: Paclitaxel, i/v; Carboplatin, i/v, from 19-Dec-2022 to 8-Aug-2023; Capecitabine, per os, since 13-Sep-2023 |
| Date of Draw | 2024/5/2 |
| Processing | Single spin |
| Weight, kg | 74 |
| Pathology Report | Invasive carcinoma of no special type (NST) of the right breast, tumor size: 3.4 cm x 4.0 cm x 4.2 cm. Mts: axillary lymph nodes; Lungs. |
| Grade | G3 |
| COVID-19 Vaccination | Unvaccinated |
| Clinical diagnosis | TNBC: Invasive carcinoma of no special type (NST) |
| T (Tumor) | ycT2 |
| HIV, HBV, HCV, RPR | Negative |
| Location Country | Ukraine |
| Smoking History | Non-smoker |
| Cancer History and Relapses | No |
